Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2903-2913

  Betts, Joanna C ^a   McLaren, Alistair ^a   Lennon, Mark G ^a   Kelly, Fiona M ^a   Lukey, Pauline T ^a   Blakemore, Steve J ^a   Duncan, Ken ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; ANTIMYCOBACTERIAL AGENT; BACTERIAL PROTEIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE; INHA PROTEIN; ISONIAZID; KASA PROTEIN; KASB PROTEIN; MYCOLIC ACID; OXIDOREDUCTASE; THIOLACTOMYCIN; TRICLOSAN; UNCLASSIFIED DRUG;

ARTICLE; DNA MICROARRAY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTITUBERCULAR AGENTS; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION REGULATION, BACTERIAL; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OPERON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; THIOPHENES; TRICLOSAN; UP-REGULATION;

EID: 0041922652     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2903-2913.2003     Document Type: Article

References (33)

1. Alland, D., I. Kramnik, T. R. Weisbrod, L. Otsubo, R. Cerny, L. P. J. W. Miller, and B. R. Bloom. 1998. Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL) - the effect of isoniazid on gene expression in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 95:13227-13232.
2. Bammert, G., and J. Fostel. 2000. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob. Agents Chemother. 44:1255-1265.
3. Banerjee, A., E. Dubnau, A. Quemard, A. S. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. W. de Lisle, and W. R. Jacobs. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
4. Barry, C. E., M. Wilson, R. Lee, and G. K. Schoolnik. 2000. DNA microarrays and combinatorial chemical libraries: tools for the drug discovery pipeline. Int. J. Tuberc. Lung Dis. 4:S189-S193.
5. Betts, J. C. 2002. Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis. IUBMB Life 53:239-242.
6. Betts, J. C., P. T. Lukey, L. C. Robb, R. A. McAdam, and K. Duncan. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43:717-731.
7. Bond, B., D. Virley, N. Cairns, A. Hunter, G. Moore, S. Moss, A. Mudge, F. Walsh, E. Jazin, and P. Preece. 2002. The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. Mol. Brain Res. 106:101-116.
8. Braibant, M., P. Gilot, and J. Content. 2000. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol. Rev. 24:449-467.
9. Brennan, P. J., and H. Nikaido. 1995. The envelope of mycobacteria. Annu. Rev. Biochem. 64:29-63.
10. Chan, P., R. Macarron, D. Payne, M. Zalacain, and D. Holmes. 2002. Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets Infect. Disord. 2:291-308.
11. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. G. S. Harris, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Conner, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osbourne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
12. Douglas, J. D., S. J. Senior, C. Morehouse, B. Phetsukiri, I. B. Campbell, G. S. Besra, and D. E. Minnikin. 2002. Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. Microbiology 148:3101-3109.
13. Eriksson, L., E. Johansson, N. Kettaneh-Wold, and S. Wold. 1999. Introduction to multi- and megavariate data analysis using projection methods (PCA and PLS). Umetrics.
14. Gmuender, H., K. Kuratli, K. Di Padova, C. Gray, W. Keck, and S. Evers. 2001. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. 11:28-42.
15. Hastie, T., R. Tibshirani, and J. Friedman. 2001. The elements of statistical learning - data mining, inference, and prediction. Springer-Verlag, New York, N.Y.
16. Hayashi, T., O. Yamamoto, H. Sasaki, H. Okazaki, and A. Kawaguchi. 1984. Inhibition of fatty acid synthesis by the antibiotic thiolactomycin. J. Antibiot. 37:1456-1461.
17. Heath, R. J., S. W. White, and C. O. Rock. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
18. Kremer, L., J. D. Douglas, A. R. Baulard, C. Morehouse, M. R. Guy, D. Alland, L. G. Dover, J. H. Lakey, W. R. Jacobs, Jr., P. J. Brennan, D. E. Minnikin, and G. S. Besra. 2000. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275:16857-16864.
19. Larsen, M. H., C. Vilcheze, L. Kremer, G. S. Besra, L. Parsons, M. Salfinger, L. Heifets, M. H. Hazbon, D. Alland, J. C. Sacchettini, and W. R. Jacobs. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
20. Marton, M., J. DeRisi, H. Bennett, V. Iyer, M. Meyer, C. Roberts, R. Stoughton, J. Burchard, D. Slade, H. Dai, D. Bassett, L. Hartwell, P. Brown, and S. Friend. 1998. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature 4:1293-1301.
21. McMurry, L., P. McDermott, and S. Levy. 1999. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 43:711-713.
22. Mdluli, K., R. A. Slayden, Y. Q. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D. M. J. Crane, and C. E. Barry. 1998. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
23. Ng, W., K. Kazmierczak, G. Robertson, R. Gilmour, and M. Winkler. 2003. Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. J. Bacteriol. 185:359-370.
24. O'Brien, R. J., and P. P. Nunn. 2001. The need for new drugs against tuberculosis - obstacles, opportunities, and next steps. Am. J. Respir. Crit. Care Med. 163:1055-1058.
25. Parikh, S. L., G. P. Xiao, and P. J. Tonge. 2000. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39:7645-7650.
26. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, and J. S. Blanchard. 1995. Enzymic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
27. Schaeffer, M. L., G. Agnihotri, C. Volker, H. Kallender, P. J. Brennan, and J. T. Lonsdale. 2001. Purification and biochemical characterization of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthases KasA and KasB. J. Biol. Chem. 276:47029-47037.
28. Slayden, R. A., R. E. Lee, J. W. Armour, A. M. Cooper, I. M. Orme, P. J. Brennan, and G. S. Besra. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. 40:2813-2819.
29. Slayden, R. A., R. E. Lee, and C. E. Barry. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525.
30. Talaat, A. M., P. Hunter, and S. A. Johnston. 2000. Genome-directed primers for selective labeling of bacterial transcripts for DNA microarray analysis. Nat. Biotechnol. 18:679-682.
31. Vilcheze, C., H. R. Morbidoni, T. R. Weisbrod, H. Iwamoto, M. Kuo, J. C. Sacchettini, and W. R. Jacobs. 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182:4059-4067.
32. Villalain, J., C. Mateo, F. Aranda, S. Shapiro, and V. Micol. 2001. Membranotropic effects of the antibacterial agent triclosan. Arch. Biochem. Biophys. 390:128-136.
33. Wilson, M., J. DeRisi, H. H. Kristensen, P. Imboden, S. Rane, P. O. Brown, and G. K. Schoolnik. 1999. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci. USA 96:12833-12838.